Tables 1 to 3 show the top 10 drugs for the year 1 July 2025 to 30 June 2026. The figures are based on PBS and RPBS prescriptions from the date of supply.

Table 1 Top 10 PBS and RPBS drugs by DDD/1000 population/day

Drug DDD/1000 population/day

1. rosuvastatin

96.70

2. atorvastatin

73.26

3. sertraline

33.30

4. escitalopram

30.36

5. pantoprazole

29.80

6. perindopril

28.15

7. candesartan

26.45

8. denosumab

24.39

9. levothyroxine

23.37

10. ramipril

22.99

Table 2 Top 10 PBS and RPBS drugs by prescription counts

Drug Prescriptions

1. rosuvastatin

16,713,299

2. pantoprazole

11,112,856

3. atorvastatin

10,861,917

4. esomeprazole

7,677,309

5. escitalopram

6,526,324

6. sertraline

6,345,132

7. perindopril

6,168,074

8. metformin

6,099,200

9. cefalexin

5,151,186

10. amoxicillin

4,826,012

Table 3 Top 10 PBS and RPBS drugs by cost to government (does not include rebates)

Drug Cost to government Prescriptions Main indications

1. pembrolizumab

$664,648,568

79,051

cancer immunotherapy

2. elexacaftor+tezacaftor+ivacaftor with ivacaftor

$619,628,158

30,503

cystic fibrosis

3. dupilumab

$619,293,030

360,888

severe asthma, atopic eczema

4. nivolumab

$458,251,347

64,690

cancer immunotherapy

5. semaglutide

$395,871,168

3,248,779

type 2 diabetes, obesity

6. aflibercept

$361,469,701

482,685

age-related macular degeneration

7. upadacitinib

$360,273,174

246,474

atopic dermatitis, inflammatory arthritides

8. daratumumab

$310,953,655

44,260

multiple myeloma, light chain amyloidosis

9. apixaban

$305,948,100

4,681,549

prevention and treatment of thrombosis

10. ocrelizumab

$251,510,441

15,345

multiple sclerosis

DDD = defined daily dose; PBS = Pharmaceutical Benefits Scheme; RPBS = Repatriation Pharmaceutical Benefits Scheme The cost figures are cost to government, excluding rebates and any patient contributions. The prescription and DDD/1000 population/day figures include under co-payment (non-subsidised) prescriptions. DDD/1000 population/day is a more useful measure of drug utilisation than prescription counts. It approximates how many people in every thousand are taking the drug every day. DDD includes use in combination products. The calculation is based on World Health Organization (WHO) methodology and ABS 3101.0 – Australian Demographic Statistics for December 2025. The tables do not include items dispensed under the Opioid Dependence Treatment (ODT) Community Pharmacy Program (buprenorphine, buprenorphine with naloxone, and methadone) due to differences in how these products are listed on the PBS compared to other products. Prescription counts for some drugs may be affected by the staggered introduction of 60-day PBS prescriptions, which started on 1 September 2023; for example, atorvastatin, perindopril and rosuvastatin were eligible from the beginning and metformin from 1 March 2024. A full list of eligible drugs is available here. Source: Department of Health, Disability and Ageing, November 2026. © Commonwealth of Australia

Australian Prescriber welcomes Feedback.

 

References